Maxim Group Trims PAVmed (NASDAQ:PAVM) Target Price to $3.00

PAVmed (NASDAQ:PAVMGet Rating) had its price objective lowered by equities research analysts at Maxim Group to $3.00 in a research report issued on Tuesday, Stock Target Advisor reports. The firm presently has a “na” rating on the stock. Maxim Group’s price objective suggests a potential upside of 183.02% from the company’s current price.

PAVM has been the subject of a number of other research reports. Zacks Investment Research cut shares of PAVmed from a “hold” rating to a “sell” rating in a research note on Saturday. Cantor Fitzgerald reissued an “overweight” rating on shares of PAVmed in a report on Saturday, February 12th.

Shares of PAVmed stock traded up $0.03 during trading on Tuesday, reaching $1.06. The company’s stock had a trading volume of 22,149 shares, compared to its average volume of 2,419,489. PAVmed has a 52-week low of $0.94 and a 52-week high of $9.70. The company has a market cap of $93.24 million, a price-to-earnings ratio of -1.56 and a beta of 0.22. The firm’s 50-day moving average is $1.27 and its two-hundred day moving average is $2.23.

PAVmed (NASDAQ:PAVMGet Rating) last announced its quarterly earnings data on Tuesday, March 29th. The company reported ($0.15) earnings per share (EPS) for the quarter. The firm had revenue of $0.30 million for the quarter. As a group, analysts predict that PAVmed will post -0.89 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PAVM. Morgan Stanley increased its stake in shares of PAVmed by 27.7% during the second quarter. Morgan Stanley now owns 766,296 shares of the company’s stock valued at $4,905,000 after buying an additional 166,293 shares during the period. SG Americas Securities LLC bought a new stake in PAVmed in the third quarter valued at $289,000. Raymond James & Associates increased its position in PAVmed by 111.9% during the 3rd quarter. Raymond James & Associates now owns 89,385 shares of the company’s stock valued at $763,000 after purchasing an additional 47,212 shares during the period. Principal Financial Group Inc. raised its holdings in PAVmed by 31.2% in the 3rd quarter. Principal Financial Group Inc. now owns 15,078 shares of the company’s stock worth $129,000 after purchasing an additional 3,585 shares in the last quarter. Finally, BlackRock Inc. raised its holdings in PAVmed by 1.2% in the 3rd quarter. BlackRock Inc. now owns 4,703,518 shares of the company’s stock worth $40,168,000 after purchasing an additional 57,855 shares in the last quarter. Institutional investors and hedge funds own 30.31% of the company’s stock.

About PAVmed (Get Rating)

PAVmed Inc operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE).

Read More

Stock Target Advisor logo

Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with's FREE daily email newsletter.